SET APPOINTMENT

Potential Annual Savings Using LUMASON® Ultrasound Enhancing Agent

You can save your institution time and money by reducing the number of sub-optimal studies performed.

Enter the number of echo studies you perform annually to see the savings for your institution. Although all other values entered are based on published data, they can be amended to reflect your institution specific data.

Input
Number of Echo Studies*

Annual number of echo studies performed in the lab

– +
CALCULATE
Operations Cost Non-Contrast

The operations cost from an echo lab to perform single study.

Sonographers Performing Studies

Study cost at 1 hour per study

Number of Sub-Optimal Studies

ASE Guidelines cite 20% of all echo studies are sub-optimal requiring an additional study.

Cardiology Study Time
% Inconclusive/hosp. Admission

% of inconclusive requiring hospital admission

% Inconclusive requiring CTA

% of non-contrast users whose inconclusive study requires coronary CT angiography

% Inconclusive Go t Nuclear MP

% of inconclusive echo studies from non-contrast users going on to further study Nuclear MPI

% Inconclusive Cardiac MRI

% inconclusive going to cardiac MRI

Cost of Hosp. Admit Overnight
Cost of Coronary CTA

Cost of Nuclear MPI

Cost of Cardiac MRI

Operations Cost with Contrast

Pass Through Eligible %

% of patients who qualify as medicare

Pass Through Reimbursement

Additional reimbursement minimum depending on nature of procedure.

Cardiology Study Time w/o Contrast
% of Private Pay

What is the % of private payer patients compared to medicare patients

Potential Annual Savings Using LUMASON® Ultrasound Enhancing Agent

See how the sub-optimal studies are reduced and the subsequent annual savings for your institution.

Sub-Optimal Studies Reduced

Value of performing the initial echo study using contrast as opposed to risking a sub-optimal study requiring further diagnostic testing or an additional echo study.

10%

Annual Savings

$11,854
Sub-Optimal Studies Reduced by 10% = $0 in savings
View Formula
Back
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
INDICATIONS AND USAGE1

LUMASON® is an ultrasound contrast agent indicated for use:

  • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
  • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
  • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients
CONTRAINDICATIONS1

LUMASON® is contraindicated in patients with:

  • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON
IMPORTANT SAFETY INFORMATION1
WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

  • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
  • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of LUMASON [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].1

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON is a registered trademark of Bracco Diagnostics Inc.

  1. 1. LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; November 2019.
  2. 2. Data on file. Bracco Diagnostics Inc. based on 2019 LUMASON® Ultrasound Enhancing Agent Reimbursement Resource Kit: July 2020.
  3. 3. Data on file. Bracco Diagnostics Inc. based on IAC Standards and Guidelines for Adult Echocardiography Accreditation: July 2020.
  4. 4. Data on file. Bracco Diagnostics Inc. based on Guidelines for the Cardiac Sonographer in the Performance of Contrast Echocardiography: Recommendations of the American Society of Echocardiography Council on Cardiac Sonography: July 2020.
  5. 5. Data on file. Bracco Diagnostics Inc. based on 2020 LUMASON® Ultrasound Enhancing Agent Reimbursement Resource Kit - HOPPS: July 2020.
  6. 6. Data on file. Bracco Diagnostics Inc. based on U.S. Hospital Use of Echocardiography: July 2020.
  7. 7. Data on file. Bracco Diagnostics Inc. based on Imaging Decision Pathways by Urgent and Elective Patients: July 2020.
  8. 8. Data on file. Bracco Diagnostics Inc. based on Healthcare Bluebook – Your Guide to Fair Pricing for Healthcare Services: July 2020.
  9. 9. Data on file. Bracco Diagnostics Inc. based on 2020 LUMASON® Ultrasound Enhancing Agent Reimbursement Resource Kit - Physician Office and IDTF: July 2020.
  10. 10. Data on file. Bracco Diagnostics Inc. based on Echocardiography Procedures in Medicare Outpatient: July 2020.
Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446

© 2020 Bracco Diagnostics Inc. All Rights Reserved.